Core Viewpoint - The company has announced a "Quality Improvement and Efficiency Enhancement Action Plan" aimed at enhancing operational quality, market competitiveness, and investor returns in response to regulatory initiatives and market conditions [1]. Group 1: Operational Focus - The company will concentrate on its core business, aiming to improve operational quality and efficiency by reducing costs and expanding market presence in the "big health" industry [1][2]. - The company plans to leverage opportunities from national procurement policies to increase market share of selected products and ensure stable supply in designated regions [2]. Group 2: Innovation and Product Development - The company aims to strengthen its product line by enhancing research and development capabilities, focusing on high-difficulty generics and innovative drugs, and collaborating with renowned research institutions [4]. - The company will accelerate the launch of new products and optimize resource allocation for ongoing projects, ensuring a dynamic evaluation of existing products for market potential [4]. Group 3: Investor Relations and Returns - The company has distributed a total of 607 million yuan in dividends since its listing in 2015 and plans to enhance investor returns through increased dividend frequency and ratios [5]. - The company emphasizes transparent communication with investors through various channels, including shareholder meetings and performance briefings, to foster a better understanding of its operations [5][6]. Group 4: Governance and Compliance - The company is committed to adhering to regulatory requirements and improving its governance structure to protect the interests of all shareholders, particularly minority investors [6][7]. - The company will enhance the compliance awareness of its key personnel and ensure effective risk management through various supervisory mechanisms [7]. Group 5: Strategic Development - The company will utilize the advantages of the Hainan Free Trade Port to develop a collaborative industrial system and enhance production efficiency through partnerships and contract manufacturing [3]. - The company aims to integrate digital and intelligent technologies into its operations to drive innovation in drug development and production processes [2][3].

（文章来源：证券日报） 证券日报网讯 12月30日，灵康药业发布公告称，公司发布"提质增效重回报"行动方案，提出七项举 措：一、聚焦主责主业，努力提升经营质量和效益；二、强化创新驱动，进一步丰富公司产品线布局； 三、注重投资者回报，共享经营成果；四、提升信披质量，加强投资者关系管理；五、优化公司治理， 提升规范运作水平；六、提升合规意识，强化"关键少数"责任；七、其他说明。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为深入贯彻落实《国务院关于进一步提高上市公司质量的意见》要求，积极 响应上海证券交易所《关于开展沪市公司提质增效重回报专项行动的倡议》，灵 康药业集团股份有限公司（"本公司"或"公司"）结合自身发展战略和实际经营 情况，制定"提质增效重回报"行动方案，以进一步提升公司经营质量和市场竞 争力，增强投资者回报。方案内容如下： 一、聚焦主责主业，努力提升经营质量和效益 证券代码：603669 证券简称：灵康药业 公告编号：2025-079 灵康药业集团股份有限公司 关于"提质增效重回报"行动方案的公告 公司将聚焦主责主业，以市场为导向，提质降本，深挖存量，拓展新量；强 化资本运作，继续加大在"大健康"产业的布局，延伸在"大健康"领域产业链， 加速企业产业升级和市场拓展，提升整体竞争力。 公司积极抢抓新一轮国采及国采到期续约机遇，推动中选国采品种的市场放 量，保障好中选国采品种在中选区域的产品供应；密切关注集中带量采购政策， 做好政策信息的收集和研判，积极响应政策并制定相应策略措施 ...

Group 1 - Hainan Airlines (600221) focuses on international, domestic, and regional air passenger and cargo transportation, operating nearly 1800 routes and covering all provinces in China, as well as over 100 international routes [1][30] - Hainan Airport (600515) operates major airports in Hainan and is involved in airport construction, management, and related industries, including aircraft maintenance and logistics [2][31] - Zhongtung High-tech (000657) is a state-owned enterprise focusing on the tungsten and hard alloy industry, with a complete industrial chain from tungsten ore to products, and is involved in high-end manufacturing sectors [3][32] Group 2 - Jinpan Technology (688676) is a key player in the new energy sector, specializing in the research and manufacturing of power distribution and control equipment, benefiting from supportive policies in Hainan [4][33] - Haixia Co., Ltd. (002320) controls important maritime transport routes, enhancing its passenger and cargo transport services, and is positioned to benefit from increased demand post-border closure [5][34] - Hainan Mining (601969) focuses on mineral resource extraction and processing, with products supporting the new energy battery industry, and is exploring green development models [6][35] Group 3 - Hainan Rubber (601118) is a leading enterprise in natural rubber production, extending its business into rubber products and international trade, leveraging Hainan's free trade policies [7][36] - Guangsheng Nonferrous (600259) specializes in non-ferrous metal mining and smelting, with a focus on rare earths and tungsten, essential for high-end manufacturing and new energy sectors [8][37] - Haima Automobile (000572) is transitioning into the new energy vehicle sector, supported by Hainan's policies, and is expanding its production capabilities [9][38] Group 4 - Haide Co., Ltd. (000567) focuses on distressed asset management, with a strategy to optimize asset allocation in the region, and is involved in photovoltaic projects [10][39] - Hainan Public Transport Group (603069) provides passenger transport services and is enhancing its operations through the integration of duty-free services [11][40] - Junda Co., Ltd. (002865) is engaged in the new energy sector, focusing on photovoltaic battery research and manufacturing, and is expanding its market presence [12][41] Group 5 - Luoniushan (000735) is involved in livestock farming and related industries, leveraging Hainan's agricultural resources to expand its market [13][42] - Jingliang Holdings (000505) focuses on oil processing and food manufacturing, utilizing Hainan's logistics advantages for trade [14][43] - Hainan Coconut Island (600238) specializes in alcoholic beverages, particularly health wines, and is expanding its market through tourism channels [15][44] Group 6 - Hainan Haiyao (000566) is a pharmaceutical manufacturer focusing on chemical raw materials and traditional Chinese medicine, benefiting from supportive policies for the pharmaceutical industry [16][45] - Hainan Ruize (002596) produces construction materials and is involved in tourism, aligning its business with Hainan's infrastructure development [17][46] - Hainan Expressway (000886) operates key highways in Hainan and is expanding its business through tourism and duty-free services [18][47] Group 7 - Puli Pharmaceutical (300630) specializes in chemical drug development and international market expansion, leveraging Hainan's trade policies [19][48] - Shennong Technology (300189) focuses on seed research and production, aiming to expand its market through trade policies [20][49] - Shuangcheng Pharmaceutical (002693) is dedicated to peptide drug development and international market expansion, supported by Hainan's policies [21][50] Group 8 - Xinlong Holdings (000955) specializes in non-woven fabrics and related products, with a focus on medical and industrial applications, and is exploring export opportunities [22][51] - ST Intercontinental (600759) is involved in oil and gas exploration and is expanding into the hydrogen energy sector [23][52] - Huawen Group (000793) operates in media, tourism, and supply chain services, aiming for growth through Hainan's logistics advantages [24][53]

（文章来源：证券日报） 证券日报网讯 12月24日，灵康药业发布公告称，公司2025年第三次临时股东会审议通过《关于聘任 2025年度审计机构的议案》。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：603669 证券简称：灵康药业 公告编号：2025-078 灵康药业集团股份有限公司 2025年第三次临时股东会决议公告 本次会议是否有否决议案：无 一、 会议召开和出席情况 二、 议案审议情况 审议结果：通过 | 1、出席会议的股东和代理人人数 | 212 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 311,458,143 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 44.2699 | | 份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次会议由公司董事会召集，由公司董事长陶灵萍女士主持。本次会议的召 (一) 股东会召开的时间：2025 年 12 月 24 日 (二) 股东会召开的地点：浙江省杭州市上城区民心路 100 号万银国际大厦 27 层，浙江灵康药业有限公司会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持 ...

上海东方华银律师事务所 法律意见书 上海东方华银律师事务所 关于灵康药业集团股份有限公司 2025 年第三次临时股东会 之 法律意见书 上海东方华银律师事务所 上海市虹桥路 1591 号虹桥迎宾馆 34 号楼 电话：(8621) 68769686 上海东方华银律师事务所 法律意见书 2025 年第三次临时股东会之法律意见书 致：灵康药业集团股份有限公司 上海东方华银律师事务所（以下简称"本所"）接受灵康药业集团股份有限 公司（以下简称"贵司"或"公司"）委托，就贵司召开 2025 年第三次临时股 东会的有关事宜，根据《中华人民共和国公司法》（以下简称《公司法》）、《上 市公司股东会规则》（以下简称《股东会规则》）等法律、法规和其他规范性文 件以及《灵康药业集团股份有限公司章程》（以下简称《公司章程》）的有关规 定，出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的本次股东会的相关资料， 包括但不限于公司召开 2025 年第三次临时股东会的通知、公司 2025 年第三次临 时股东会的议程、议案及决议等文件资料，同时听取了公司董事会秘书就有关事 实的陈述和说明。公司已向本所作出保证和承诺，保证公司向 ...

灵康药业集团股份有限公司 2025 年第三次临时股东会会议资料 (603669) 二〇二五年十二月 灵康药业集团股份有限公司 2025 年第三次临时股东会会议资料 灵康药业集团股份有限公司 2025 年第三次临时股东会会议资料目录 | 2025 | 年第三次临时股东会会议议程 2 | | --- | --- | | 2025 | 年第三次临时股东会会议须知 4 | | 议案一：关于聘任 | 2025 年度审计机构的议案 5 | 第 1 页 共 7 页 灵康药业集团股份有限公司 2025 年第三次临时股东会会议资料 灵康药业集团股份有限公司 2025 年第三次临时股东会会议议程 现场会议时间：2025 年 12 月 24 日 14 点 30 分 现场会议地点：浙江省杭州市上城区民心路 100 号万银国际大厦 27 层，浙江灵 康药业有限公司会议室 议程： 一、 签到、宣布会议开始 1、与会人员签到，领取会议资料；股东及股东代理人同时提交身份证明材 料（授权委托书、营业执照复印件、身份证复印件等）并领取《表决票》； 五、等待网络投票结果 第 2 页 共 7 页 召集人：公司董事会 主持人：董事长陶灵萍 2、主持人 ...

Core Viewpoint - Lingkang Pharmaceutical Group Co., Ltd. has decided not to exercise the downward adjustment of the conversion price for its convertible bonds, despite triggering the conditions for such an adjustment due to stock price performance [2][5][6]. Group 1: Convertible Bond Details - The company issued 5.25 million convertible bonds on December 1, 2020, with a total amount of 525 million yuan and a maturity of 6 years [3]. - The initial conversion price was set at 8.81 yuan per share, which has been adjusted multiple times, with the latest price being 6.50 yuan per share [3][4]. - The conversion period for the bonds is from June 7, 2021, to November 30, 2026 [6]. Group 2: Price Adjustment Conditions - As of December 9, 2025, the stock price has been below 85% of the current conversion price for at least 15 trading days within a 30-day period, triggering the price adjustment clause [2][5]. - The board of directors has decided not to propose a downward adjustment for the conversion price, considering various factors including the company's fundamentals and market conditions [5][6]. - If the conditions for downward adjustment are triggered again within the next month, the company will still not propose an adjustment, and the board will reassess the situation starting January 12, 2026 [2][6].

Core Viewpoint - Lingkang Pharmaceutical announced that its stock price has fallen below 85% of the current conversion price for at least 15 trading days within a consecutive 30-day period, triggering the downward adjustment clause for its convertible bonds [2] Group 1: Company Actions - The company's board of directors has decided not to exercise the right to adjust the conversion price of the "Lingkang Convertible Bonds" downward at this time [2] - The company will not propose a downward adjustment plan if the conditions for the conversion price adjustment are triggered again within the next month, from December 10, 2025, to January 9, 2026 [2] - Starting from January 12, 2026, if the conditions for the downward adjustment are triggered again, the board will convene to review whether to exercise the right to adjust the conversion price [2]